Research Topics
Species | Michael A PulsipherSummaryAffiliation: University of Utah Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant ConsortiumMichael A Pulsipher
Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
Biol Blood Marrow Transplant 16:1212-21. 2010....- Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor ProgramMichael A Pulsipher
Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
Blood 121:197-206. 2013..In summary, this study provides extensive detail regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profiles that can be targeted with interventions to minimize toxicity... - National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-sMichael A Pulsipher
Primary Children s Medical Center, University of Utah School of Medicine Huntsman Cancer Institute, Division of Hematology BMT, Salt Lake City, Utah 84132, USA
Biol Blood Marrow Transplant 18:334-47. 2012..Our panel of late effects experts also provides recommendations for follow-up and therapy of selected post-HCT organ and endocrine complications in pediatric patients... - Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor ProgramMichael A Pulsipher
University of Utah School of Medicine, Primary Children s Hospital, Salt Lake City, UT 84132 2408, USA
Blood 113:3604-11. 2009..In addition, women and larger donors are at higher risk for donation-related AEs... 
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313Michael A Pulsipher
Primary Children s Medical Center, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84132 2408, USA
Blood 114:1429-36. 2009..01). Favorable outcomes can be achieved with RIC approaches in pediatric patients in remission who are ineligible for myeloablative transplantation. This study was registered at www.clinicaltrials.gov as #NCT00795132...- Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell doseMichael A Pulsipher
University of Utah School of Medicine, Primary Children s Hospital, Salt Lake City, UT 84132 2408, USA
Blood 114:2606-16. 2009..004; 38% versus 21% RI/NMA, P = .004) but did not increase the risk of GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00785525... - A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)Michael A Pulsipher
Division of Hematology Blood and Marrow Transplant, Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84132 2408, USA
Br J Haematol 147:691-9. 2009..A phase III trial to test whether sirolimus decreases relapse and improves outcome after transplantation for ALL is ongoing... - Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,Michael A Pulsipher
Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, Utah 84113, USA
Biol Blood Marrow Transplant 17:291-9. 2011..Collaboration with similar study groups in Europe and Asia will be pursued... - High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Michael A Pulsipher
Primary Children s Medical Center, Division of Hematology Blood and Marrow Transplantation, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
Biol Blood Marrow Transplant 17:S137-48. 2011..Trials comparing chemotherapy and HSCT must obtain sufficient data about therapy and stratify the analysis to assess the outcomes of best-chemotherapy with best-HSCT approaches... 
Nonmyeloablative transplantation in children. Current status and future prospectsM A Pulsipher
Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Utah School of Medicine, Salt Lake City, Utah, USA
Hematol Oncol Clin North Am 15:809-34, vii-viii. 2001..Finally, use of this approach to establish partial donor chimerism may provide an immunologic platform that will allow specific cellular therapies, targeted gene therapy, or immunologic tolerance in solid organ transplantation...- Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMMLM A Pulsipher
Blood and Marrow Transplant Program, Salt Lake City, UT 84132, USA
Bone Marrow Transplant 33:113-5. 2004..This is the first published report of a patient with non-monosomy-7 JMML responding to post-transplant immunomodulation and suggests a role for DLI plus IFN in these patients... - Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?Michael A Pulsipher
Blood and Marrow Transplant Program, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
Pediatr Blood Cancer 43:523-33. 2004..Imatinib mesylate (STI-571, Gleevec) and reduced intensity conditioning stem cell transplantation (RIC) are two promising new tools that offer potential for decreasing therapy associated morbidity for patients with CML... - Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donorsMichael A Pulsipher
Primary Children s Medical Center, Salt Lake City, Utah 84113, USA
Pediatr Blood Cancer 46:422-33. 2006..Short and long-term risks of G-CSF administration and leukopheresis are not well understood in the pediatric population... - The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplantMerideth M M Wendland
Department of Radiation Oncology, Huntsman Cancer Hospital and the University of Utah, Salt Lake City, Utah 84112, USA
Am J Clin Oncol 30:156-62. 2007..We examined the role of involved field radiation therapy (IFRT) in this setting... - A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) studyHaydar Frangoul
Department of Pediatrics, Vanderbilt University, Nashville, TN 37232 2573, USA
Blood 110:4584-7. 2007..Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD... - Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levelsJakub Tolar
Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 18:1007-11. 2012..CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m(2)), and antithymocyte globulin was associated with excessive organ toxicity... - Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapseMichael A Pulsipher
Division of Hematology BMT, Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, Utah
Biol Blood Marrow Transplant 15:62-71. 2009.... - Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyriaJohn D Phillips
Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
Blood 109:2618-21. 2007..The Hb F level of 59.5% suggests a role for GATA-1 in globin switching. A bone marrow allograft corrected both the porphyria and the thalassemia... - The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin diseaseMerideth M M Wendland
Department of Radiation Oncology, Huntsman Cancer Hospital and the University of Utah, Salt Lake City, UT, USA
Am J Clin Oncol 29:189-95. 2006..The potential benefit of IFRT may be underestimated because of the heterogeneity of the treatment groups. The use of IFRT was not associated with an increase in the risk of acute mortality or late events... - Lower hospital mortality and complications after pediatric hematopoietic stem cell transplantationSusan L Bratton
University of Utah School of Medicine, Department of Pediatrics, Division of Critical Care Medicine, USA
Crit Care Med 36:923-7. 2008..To assess protective and risk factors for mortality among pediatric patients during initial care after hematopoietic stem cell transplantation (HSCT) and to evaluate changes in hospital mortality... - Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningMohamed L Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 26:4912-20. 2008..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients... - Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrederic Baron
Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
J Clin Oncol 24:4150-7. 2006..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches... - Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseasesGeorge E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
Int J Hematol 76:184-9. 2002..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options... - Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplantLyle C Feinstein
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 9:266-72. 2003..4; P =.04). Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting... - Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myelomaGeorge E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 13:423-32. 2007.... - Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 110:2744-8. 2007..The latter might benefit from cytoreductive treatment before HCT... - Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive CommitteeStephan A Grupp
Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Pediatr Blood Cancer 46:414-21. 2006..We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur... - Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphomaAndrew R Rezvani
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
J Clin Oncol 26:211-7. 2008..Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting... - HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemiaFrederic Baron
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 11:272-9. 2005..Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression... - Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 monthsMary Eapen
Center for Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI 53226, USA
J Clin Oncol 24:145-51. 2006..To describe outcomes after unrelated donor stem cell transplantation (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare these with outcomes after human leukocyte antigen (HLA)-matched sibling donor HCT... - Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in childrenAnn E Woolfrey
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, USA
Int J Hematol 76:271-7. 2002..Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treatment of life-threatening immune deficiencies... - Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioningFrederic Baron
University of Liege, Liege, Belgium
Biol Blood Marrow Transplant 13:1041-8. 2007..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning...
Research Grants
- RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality LifeGalen E Switzer; Fiscal Year: 2010....
- RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality LifeMICHAEL A contact PULSIPHER; Fiscal Year: 2011....